[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [$wves](/topic/$wves) ### Top Social Posts *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "Totally agree DM1 is a huge market and $pepg very interesting. Re $WVE and INHBE may want to check out the attached post. I think there is a fairly high likelihood that $WVEs approach of further increasing adipocyte / hepatocyte lipolysis through INHBE silencing will worsen insulin sensitivity in patients who are already obese and almost certainly already have excess lipolysis as the baseline excess lipolysis is a major causal factor in insulin resistance / diabetes. I think there is a core difference in molecular profile between patients who have LoF INHBE gene variants and therein" [X Link](https://x.com/medstudentinvst/status/1979306544622895157) [@medstudentinvst](/creator/x/medstudentinvst) 2025-10-17T22:00Z XXX followers, XXX engagements "Leerink $WVE's PT to $XX from $XX reit'd Outperform & said it thinks invs should take advantage of weakness to buy ahead of add'l important catalysts which they remain optimistic investors will appreciate. $GSK $ARWR $TAK $KRRO $SNY $NTLA $BEAM $LLY $NVO $VKTX $GPCR Raymond James reit'd $WVE Outperform-$14 & said We continue to view $WVE's wholly-owned gene-editing programs as more likely LT value drivers - sees WVE-007 (INHBE) in obesity (4Q 2025) as the most important near-term stock-moving catalyst with an attractive risk/ reward skew. Leerink and Raymond James said in their notes to" [X Link](https://x.com/Quantumup1/status/1963305424389550134) [@Quantumup1](/creator/x/Quantumup1) 2025-09-03T18:17Z 3847 followers, 7099 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Totally agree DM1 is a huge market and $pepg very interesting. Re $WVE and INHBE may want to check out the attached post. I think there is a fairly high likelihood that $WVEs approach of further increasing adipocyte / hepatocyte lipolysis through INHBE silencing will worsen insulin sensitivity in patients who are already obese and almost certainly already have excess lipolysis as the baseline excess lipolysis is a major causal factor in insulin resistance / diabetes. I think there is a core difference in molecular profile between patients who have LoF INHBE gene variants and therein"
X Link @medstudentinvst 2025-10-17T22:00Z XXX followers, XXX engagements
"Leerink $WVE's PT to $XX from $XX reit'd Outperform & said it thinks invs should take advantage of weakness to buy ahead of add'l important catalysts which they remain optimistic investors will appreciate. $GSK $ARWR $TAK $KRRO $SNY $NTLA $BEAM $LLY $NVO $VKTX $GPCR Raymond James reit'd $WVE Outperform-$14 & said We continue to view $WVE's wholly-owned gene-editing programs as more likely LT value drivers - sees WVE-007 (INHBE) in obesity (4Q 2025) as the most important near-term stock-moving catalyst with an attractive risk/ reward skew. Leerink and Raymond James said in their notes to"
X Link @Quantumup1 2025-09-03T18:17Z 3847 followers, 7099 engagements
/topic/$wves/posts